Vivos (RDGL) Short term Debt (2011 - 2023)

Vivos (RDGL) posted Short term Debt of $10000.0 for Q3 2023, down 75.0% sequentially from $40000.0 in Q1 2018.

Vivos (RDGL) Short term Debt (2011 - 2023) Analysis & Trends

Vivos has reported Short term Debt for 9 years, with the latest figure at $10000.0 in Q3 2023.

Quarterly Short term Debt changed N/A year-over-year to $10000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $10000.0 (changed N/A YoY) and the FY2016 annual result came in at $332195.0, down 74.06% from the prior year.
Short term Debt fell to $10000.0 in Q3 2023 per RDGL's latest filing, from $40000.0 in the prior quarter.
Over five years, Short term Debt peaked at $10000.0 in Q3 2023 and troughed at $10000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.24 Bn	193.64 Bn	7.27 Bn
2	Stryker	128.63 Bn	125.15 Bn	4.50 Bn
3	Medtronic	119.19 Bn	109.97 Bn	6.41 Bn
4	Boston Scientific	73.51 Bn	72.97 Bn	3.85 Bn
5	Edwards Lifesciences	52.11 Bn	47.85 Bn	1.35 Bn
6	Dexcom	34.64 Bn	32.70 Bn	830.00 Mn
7	GE HealthCare Technologies	34.01 Bn	31.90 Bn	2.18 Bn
8	Koninklijke Philips	26.40 Bn	23.08 Bn	4.55 Bn
9	Steris	23.14 Bn	22.65 Bn	684.20 Mn
10	Vivos	24.90 Mn	23.34 Mn	-3,105.00

Download Data